The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.
Medicare has agreed to pay for the Alzheimer's treatment Leqembi, a major turning point for patients who are diagnosed with the early stages of the disease.
Medicare coverage is crucial for most patients to have any hope of being able to afford Leqembi.
Eisai has priced Leqembi at $26,500 per year before insurance coverage, which is extraordinarily expensive for Medicare patients, who have a median income of about $30,000.
Patients with traditional Medicare will pay 20% of the bill for Leqembi, according to the federal Centers for Medicare and Medicaid Services.
Persons:
Leqembi, Biogen, Tricia Neuman, Neuman
Organizations:
Reuters, Medicare, Food and Drug Administration, Services
Locations:
Cambridge , Massachusetts